CagriSema and the rise of amylin-GLP-1 combination therapy for obesity

Patients often ask me what's coming after semaglutide and tirzepatide — whether the next wave of weight-loss medications will simply be "more of the same" or something genuinely new. CagriSema, Novo Nordisk's combination of cagrilintide and semaglutide, represents the latter: it's built on a fundamentally different hormone pathway than the GLP-1/GIP medications we already use, and this year's trial data lets us evaluate, honestly, how well that new approach is actually working.

Semaglutide works through the GLP-1 receptor; tirzepatide adds GIP receptor activity. Cagrilintide, the second component of CagriSema, is different again: it's an amylin analog. Amylin is a hormone released by the pancreas alongside insulin that slows gastric emptying and promotes satiety through a separate signaling pathway than GLP-1. The idea behind pairing an amylin analog with semaglutide is that hitting two different appetite and satiety pathways simultaneously might produce weight loss beyond what either mechanism achieves alone — comparable, conceptually, to how tirzepatide's dual GLP-1/GIP approach improved on GLP-1 alone.

The headline efficacy data comes from the REDEFINE-1 trial, published in the New England Journal of Medicine, which enrolled adults with overweight or obesity. CagriSema at the 2.4 mg/2.4 mg dose produced an average weight reduction of 22.7%. I want to be direct about how to interpret this number: it is a substantial, clinically meaningful result — well within the range that improves blood pressure, blood sugar, joint pain, and overall metabolic health for most patients. But it fell short of Novo Nordisk's own pre-specified target of 25% average weight loss, and in head-to-head-style comparative data, CagriSema did not clearly outperform tirzepatide at its top approved dose. This matters for how I counsel patients: CagriSema is a genuinely effective medication, not a categorically superior one to what we already have, and I'd encourage skepticism toward any marketing that suggests otherwise until more head-to-head trial data is available.

Where CagriSema's data looks particularly strong is in patients who also have type 2 diabetes. The REIMAGINE program — three separate phase 3 trials in this population — showed CagriSema produced a 1.91% reduction in HbA1c (a key marker of long-term blood sugar control), reported as greater than what either cagrilintide or semaglutide achieved individually. Encouragingly, this benefit came with limited additional impact on gastrointestinal tolerability compared to semaglutide alone — suggesting that adding the amylin pathway doesn't simply stack more nausea and GI side effects on top of what patients already experience with GLP-1 therapy, which was a real question going into these trials.

Novo Nordisk has filed a New Drug Application for CagriSema, so a regulatory decision is expected in the coming period. If approved, I expect CagriSema to carve out a specific niche rather than simply replacing existing options: patients with type 2 diabetes who need both stronger glycemic control and weight loss may be particularly good candidates, given the REIMAGINE data, and patients who haven't achieved their goals on semaglutide alone may benefit from adding amylin-pathway activity even if they aren't candidates for or don't tolerate the GIP-based tirzepatide.

Stepping back, what I find most encouraging about CagriSema isn't any single number — it's what it represents: a genuinely new mechanism entering late-stage clinical testing, alongside the triple-agonist retatrutide and the emerging oral pill options. We are moving from a world with one or two obesity medication choices to one with a real menu of mechanisms, each with different strengths, side-effect profiles, and ideal patient populations. That is exactly the direction obesity medicine needs to go, because no single mechanism works optimally for every patient, and having more validated tools means more patients can find a treatment that truly fits their biology and their life.

My advice to patients considering any of these newer options remains consistent: don't chase the highest number in a headline. Talk to your specialist about which specific mechanism makes sense for your medical history, your other health conditions, and how your body has responded to treatments you've already tried.

Sources: REDEFINE-1 trial of CagriSema, New England Journal of Medicine, 2026; REIMAGINE phase 3 program in type 2 diabetes, Novo Nordisk, 2026.